Disease Detail

Profile Responses 0
Clinical Trials 20

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Therapy	Indication/Tumor Type	Response Type	Profile Response Detail

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02279394	Phase II	Dexamethasone Elotuzumab + Lenalidomide	Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma	Completed	USA	0
NCT02886065	Phase I	Durvalumab Durvalumab + PVX-410 Durvalumab + Lenalidomide + PVX-410	A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma	Active, not recruiting	USA	0
NCT02903381	Phase II	Dexamethasone + Lenalidomide + Nivolumab	Nivolumab + Lenalidomide + Dexamethasone In SMM	Completed	USA	0
NCT02960555	Phase II	Diphenhydramine + Isatuximab + Methylprednisolone + Ranitidine	Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma	Active, not recruiting	USA	0
NCT03301220	Phase III	Daratumumab + rHuPH20	A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma	Active, not recruiting	USA \| TUR \| SWE \| POL \| NOR \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG	3
NCT03591614	Phase I	DKK1 dendritic cell vaccine	Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma	Withdrawn	USA	0
NCT03631043	Phase I	Personalized cancer vaccine	Personalized Vaccine in Treating Participants With Smoldering Multiple Myeloma	Active, not recruiting	USA	0
NCT03839459	Phase II	Denosumab	Denosumab for Smoldering Multiple Myeloma	Active, not recruiting	USA	0
NCT04270409	Phase III	Dexamethasone + Lenalidomide Dexamethasone + Isatuximab + Lenalidomide	Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma	Active, not recruiting	USA \| TUR \| SWE \| POL \| NZL \| NOR \| LTU \| ITA \| ISR \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| AUS	3
NCT05055063	Phase I	belantamab mafodotin-blmf	A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma	Recruiting	USA	0
NCT05469893	Phase II	Teclistamab Dexamethasone + Lenalidomide	Immuno-PRISM (PRecision Intervention Smoldering Myeloma)	Recruiting	USA	0
NCT05597345	Phase II	Selinexor	Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma	Recruiting	USA	0
NCT05767359	Phase II	Ciltacabtagene autoleucel + Cyclophosphamide + Fludarabine	CAR- PRISM (PRecision Intervention Smoldering Myeloma)	Recruiting	USA	0
NCT05841550	Phase Ib/II	QS21 + TG01	The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma	Recruiting	NOR	0
NCT05955508	Phase II	Linvoseltamab	A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma	Recruiting	ESP	0
NCT06100237	Phase II	Daratumumab + Teclistamab Daratumumab + Talquetamab-tgvs	Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) (REVIVE)	Recruiting	USA	0
NCT06140524	Phase II	Linvoseltamab	A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma (LINKER-MGUS1)	Recruiting	USA \| ESP	0
NCT06183489	Phase II	Elranatamab-bcmm	Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (ERASMM)	Recruiting	NOR \| NLD \| ITA \| GRC \| FRA \| FIN	0
NCT06550895	Phase II	Daratumumab + Dexamethasone + Lenalidomide Ciltacabtagene autoleucel + Talquetamab-tgvs	A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (MonumenTAL-8)	Recruiting	USA \| AUS	0
NCT06574126	Phase II	Bortezomib + Ciltacabtagene autoleucel + Daratumumab + Dexamethasone + Lenalidomide	Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (CAR-HiRiSMM)	Recruiting	ESP	0

ID	DOID:9551
Name	smoldering myeloma
Definition	A multiple myeloma that is a slow growing type of myeloma in which abnormal plasma cells results_in too much of a single type of monoclonal antibody.
Source	DiseaseOntology.org
Alt Ids
Path	disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm multiple myeloma smoldering myeloma

We’re improving your experience!

Disease Detail

Contact

Filtering

Sorting